Share on StockTwits

Stock analysts at Roth Capital hoisted their target price on shares of BioDelivery Sciences International (NASDAQ:BDSI) to $15.50 in a report issued on Monday. The firm currently has a “buy” rating on the stock. Roth Capital’s price target would indicate a potential upside of 55.00% from the stock’s previous close.

A number of other firms have also recently commented on BDSI. Analysts at Laidlaw reiterated a “buy” rating on shares of BioDelivery Sciences International in a research note on Monday. They now have a $15.00 price target on the stock. Separately, analysts at William Blair reiterated an “outperform” rating on shares of BioDelivery Sciences International in a research note on Monday. They now have a $23.00 price target on the stock. Finally, analysts at Piper Jaffray raised their price target on shares of BioDelivery Sciences International to $24.00 in a research note on Monday. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $19.25.

Shares of BioDelivery Sciences International (NASDAQ:BDSI) traded down 1.50% on Monday, hitting $9.85. 3,068,688 shares of the company’s stock traded hands. BioDelivery Sciences International has a 52-week low of $3.86 and a 52-week high of $10.20. The stock’s 50-day moving average is $8.96 and its 200-day moving average is $7.63. The company’s market cap is $477.2 million.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Friday, May 9th. The company reported ($0.11) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.15) by $0.04. The company had revenue of $20.69 million for the quarter, compared to the consensus estimate of $11.60 million. On average, analysts predict that BioDelivery Sciences International will post $-0.59 earnings per share for the current fiscal year.

BioDelivery Sciences International, Inc (NASDAQ:BDSI) is a specialty pharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.